In stock · depth page
BPC-157 / TB-500 — recent literature (RUO)
BPC-157 and thymosin β4–adjacent repair literature
BPC-157 10 mg + TB-500 10 mg blend · literature note
For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. Literature on this page is scientific context only. This page is not a licensed drug, a wellness protocol, or a dosing guide.
Systematic reviews, sports-medicine primers, and mechanistic commentary are literature for laboratory buyers. They are not wellness copy and they are not use instructions.
How to read recent hits
Orthopaedic systematic reviews help a laboratory see evidence gaps. Sports-medicine primers that mention injectable peptides are risk and evidence-gap context, not marketing. Angiogenesis and nitric-oxide commentary supports literature identity. Keep the research-use-only frame even when a paper discusses clinical interest.
Prefer the lot-matched COA over a review abstract when a vial is released to the bench. Name the blend SKU if that is what the laboratory is ordering.
Identity
Form
Lyophilized blend, sealed vial
Strength
10 mg + 10 mg lyophilized blend
Purity
≥99% HPLC (each component; see the lot COA)
CAS
- BPC-157: 137525-51-0
- Thymosin β4 / TB-500: 77591-33-4
PubMed
Selected literature
- PMID 22950504 (2013) Sikiric et al., Current Pharmaceutical Design — BPC-157 preclinical / review (toxicity-counteraction frame)
- PMID 14554208 (2003) Staresinic et al., Journal of Orthopaedic Research — transected Achilles tendon model (preclinical)
Recent literature (2023–2026)
- PMID 40756949 (2025) Vasireddi et al., HSS Journal — systematic review of BPC-157 orthopaedic literature (predominantly preclinical)
- PMID 41476424 (2026) Mayfield et al., American Journal of Sports Medicine — injectable-peptide primer noting BPC-157 / TB-4 / TB-500 evidence gaps
- PMID 41155565 (2025) Sikiric et al., Pharmaceuticals (Basel) — BPC-157 angiogenesis / nitric-oxide discussion
- PMID 40789979 (2025) McGuire et al., Current Reviews in Musculoskeletal Medicine — narrative review of BPC-157 musculoskeletal literature (regeneration-vs-risk framing)
Literature is scientific context only. A paper does not make a research vial into a licensed medicine.
Bench reconstitution
The catalog parent is one lyophilized cake: 10 mg BPC-157 and 10 mg TB-500. Dissolve the entire cake in one bacteriostatic-water volume to the combined mg/mL the protocol specifies. Swirl until no solids remain. Do not vortex. Record solvent lot and time. This is a reconstitution volume, not a clinical dose, and it is not a standalone BPC-157 or TB-500 vial.
Diluent page: bacteriostatic water.
Storage
Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until the bench protocol calls for it. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook. Confirm the lot COA before you adopt a hold time.
Certificate of analysis
Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. This page is not a COA.
Lab FAQ
Do recent reviews prove clinical efficacy?
No. Several of them highlight evidence gaps. Use them as literature context only. Write request@pharmapeptidesrx.com to add the 10 mg + 10 mg blend to a research request. This page does not publish prices or banking details. Invoices go out from request@ only.
In this library
In stock · list price
Request from the catalog
Every vial on the catalog shows its CAD list price. Add it to your request and we email the invoice. Labs pay by Interac e-Transfer. No card checkout.